Viva Physicians Inc

What it reported doing in 2025

Educationthe organization sponsors vascular interventional advances ("viva"), the global education course for vascular medicine and intervention. Viva is conducted annually in las vegas, Nevada and on a smaller scale with other nonprofit organizations in a collaborative role both domestically and worldwide. In 2025, the annual conference was hosted live and virtually, and several educational webinars were held throughout the year.viva is sponsored by vpi and contracts with an accredited continuing medical education ("cme") provider (continued on schedule o)to approve credits for physician attendees nurses, techs, and other healthcare professionals. Viva furthers vpl's exempt purpose as both an accredited continuing medical education program and a forum for promoting the latest research findings and technology in the field of vascular medicine and intervention.in 2015, viva added a two-day program, the veins (venous endovascular interventional strategies), focused exclusively on treating patients with venous disease. This course is held annually the two days preceding the viva conference. Vpi has supported a multidisciplinary fellowship for several years. In the past seven years, additional opportunities for training fellows have been incorporated into the annual viva conference. Beginning in 2018, viva partnered with the american heart association to provide research grants for fellows and plans to continue this collaboration through 2027, as well as a grant for a collaborative sciences award for patient-oriented and clinical research in vascular science.viva is funded primarily through unrestricted educational grants from commercial supporters in accordance with standards of the american council for continuing medical education ("accme"). Viva also generates funds through registration and tuition payments from the conference attendees.vpi strives to be the premier educator in the field of vascular medicine and intervention and to associate the name "viva" with cutting edge and state-of-the-art programs that serve the public good by promoting advances in treatment of peripheral vascular disease. In 2012, vpi expanded its international educational opportunities by collaborating with international organizations to provide state of the art learning modalities and cutting-edge programs in countries such as brazil, germany, great britain, israel and china.in 2014, vpi launched a virtual viv a application that made it possible for international and military physicians to participate in the annual viv a conference remotely. Viva offers complimentary access and/or deep discounts to educational content through the virtual viva app to international physicians as well as all active military physicians.in 2025, vpi entered into an agreement with the minneapolis radiology and vascular research foundation to assume management of carve - clinically relevant vascular & endovascular surgery, an educational conference that took place from march 8, 2026 through march 11, 2026.researchvpi sponsors research and pioneering therapy in the field of vascular medicine. Vpi receives grants from industry as well as contributions from private individuals in support of pvd (peripheral vascular disease) research.vpi has managed several food and drug administration ("fda") approved studies related to pvd treatment. These trials follow good clinical practice ("gcp") protocols and require strict institutional review board ("irb") approval at each site. Viva has also provided support for nih approved clinical trials in the vascular and veins space.advocacyas part of vpi's strategic plan, patient care advocacy programs are designed to advance the field of vascular disease care and engage thought leaders and government agencies, including the u.s. Food and drug administration (fda) and the centers for medicare & medicaid services (cms).the first advocacy program was held in april 2016 and focused on the global management of critical limb ischemia (cli), one of th

Financial Efficiency

• Mission deployment rate: 80%; rating input score 80
• Program expense ratio: 93.1%; rating input score 93
• Fundraising efficiency: $128.37 raised per $1 spent on fundraising; rating input score 90; 90th percentile among comparable filings

Transparency & Controls

• Consistency checks: 93.3%; rating input score 93; 18th percentile among comparable filings
• Pay-setting controls: 3 of 6 controls in place; rating input score 50
  • Compensation committee: Missing
  • Independent consultant: Missing
  • Other Form 990s reviewed: Pass
  • Written employment contract: Missing
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: Limited
• Grant itemization coverage: 99.3%; rating input score 99; 44th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 0%; rating input score 0; 4th percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 16.7%; rating input score 68; 68th percentile among comparable filings
• Total-asset coverage ratio: 5.07; rating input score 81; 81st percentile among comparable filings
• Liabilities to assets ratio: 0.05; rating input score 61; 61st percentile among comparable filings
• Officer compensation ratio: 26%; rating input score 10; 10th percentile among comparable filings

Growth

• Program expense growth: -0.2% per year; rating input score 0; 12th percentile among comparable filings
• Revenue growth: -0% per year; rating input score 0; 8th percentile among comparable filings
• Asset growth: 7.5% per year; rating input score 100; 47th percentile among comparable filings